Step by Step


ABIM MOC Activity ID

3/21/2017 - Medical Grand Rounds: Gastroenterology and Hepatology Year in Review





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Identify relevant changes to thought and practice in Hepatitis C, primary biliary cholangitis, NAFLD (specifically NASH), portal hypertension.
  • Increase appropriate use of protein pump inhibitors (PPI) by understanding the potential side effects
  • Improve doctors ability to communicate risk of dementia and rental failure associated with PPI use.

Suggested Additional Reading:

  1. Kwok, et al., Bone; 48(2011);768-776.
  2. Targownik, et al. Gastro; 2010;138:896-904.
  3. Corley, et al. Gastro; 2010.139:93-101.
  4. Feld JJ, Jocobson IM, Hezode C, et al. Sofosbuvir and Valpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Eng J Med. 373(27):2015
  5. Drug Discovery Today, Vol. 17, Numbers 17/18, 988-997.

Marc Schwartz, MD — Division of Gastroenterology, Hepatology, and Nutrition UPMC Inflammatory Bowel Disease Center
No relationships with industry relevant to the content of this educational activity have been disclosed.
Naudia L. Jonassaint, MD MHS — Assistant Professor of Medicine and Surgery, Transplant Hepatology, UPMC
Dr. Jonaissant receives grant/research support from Gilead Sciences.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.